Characteristics and treatment outcomes of patients treated with empagliflozin in the Association of British Clinical Diabetologists (ABCD) Nationwide Empagliflozin Audit

Lack of risk factors predicting the development of genital mycotic infections among patients treated with dapagliflozin: the ABCD Nationwide Dapagliflozin Audit

KY Thong¹, M Yadagiri², P Tong³, D Barnes⁴, D Morris⁵, T Chowdhury⁶, LL Chuah⁷, M Cohen⁸, A Kennedy⁹, T Robinson¹⁰, SC Bain¹¹, KA Adamson¹², REJ Ryder² , ABCD Nationwide Dapagliflozin Audit contributors

¹University of Western Australia, Perth, Australia

The effect of dapagliflozin on HbA1c and weight after its addition to commonly prescribed dual combination diabetes medication regimes in people with type 2 diabetes in a real-world UK setting: the ABCD nationwide dapagliflozin audit

M Yadagiri¹, P Sen Gupta¹, A.Kennedy², T Pang³, L Balamuri⁴, T Robinson⁵, S Bain⁶, IW Gallen⁷, K Adamson⁸, REJ Ryder¹, the ABCD nationwide dapagliflozin audit contributors⁹

Effect of dapagliflozin on HbA1c and weight after its addition to various combinations of other diabetes medications: Association of British Clinical Diabetologist (ABCD) nationwide dapagliflozin audit

M Yadagiri¹, P Sen Gupta¹, T Pang², L.Balmuri³, T. Robinson⁴, S. Bain⁵, I.W. Gallen⁶, K A Adamson⁷ and R E J Ryder¹ on behalf of ABCD dapagliflozin audit contributors

¹Sandwell and West Birmingham NHS Trust, Birmingham, UK

The Glycaemic Response to Dapagliflozin according to Intensity of Background Diabetes Treatment or Duration of Type 2 Diabetes: the Association of British Clinical Diabetologists (ABCD) Nationwide Dapagliflozin Audit

K Y Thong¹, M Yadagiri², P S Gupta², P Winocour³, M Joshi⁴, J Wilding⁵, J W Stephens⁶, S C Bain⁶, A Robinson⁷, I W Gallen⁸, K A Adamson⁹, R E J Ryder², the ABCD nationwide dapagliflozin audit contributors¹⁰

HbA1c, weight,body mass index(BMI) and systolic blood pressure response to dapagliflozin : the Association of British Clinical Diabetologists (ABCD) nationwide dapagliflozin audit

M Yadagiri¹, P S Gupta¹, A Kennedy², T Pang³, J Clark⁴, H Pathan¹, P C Johnston⁵, R Chudleigh⁶, A Robinson⁷, I W Gallen⁸, K A Adamson⁹, R E J Ryder¹, the ABCD nationwide dapagliflozin audit contributors¹⁰

Does dapagliflozin affect the metabolic response in patients with elevated alanine aminotransferase (ALT) and Type 2 diabetes?: the Association of British Clinical Diabetologists (ABCD) nationwide dapagliflozin audit

M.Yadagiri¹, P S Gupta¹, M L Cull¹, D Price², V Oguntolu³, K Imtiaz⁴, D Barnes⁵, A Nugent⁶, A Robinson⁷, I W Gallen⁸, K A Adamson⁹, R E J Ryder¹, the ABCD nationwide dapagliflozin audit contributors¹⁰

The Glycaemic Response to Dapagliflozin among Type 2 Diabetes Patients according to Intensity of Background Diabetes Treatment or Duration of Diabetes: the Association of British Clinical Diabetologists Nationwide Dapagliflozin Audit

Does dapagliflozin affect the metabolic response in patients with elevated alanine aminotransferase (ALT) and Type 2 diabetes?: the Association of British Clinical Diabetologists (ABCD) nationwide dapagliflozin audit

M Yadagiri¹, P Sen Gupta¹, JW Stephens², A Robinson³, M Phylactou⁴, A Kennedy⁵, J Clarke⁶, J Wilding⁷, I W Gallen⁸, KA Adamson⁹, REJ Ryder¹, the ABCD nationwide dapagliflozin audit contributors¹⁰

HbA1c, weight, body mass index (BMI) and systolic blood pressure changes in the Association of British Clinical Diabetologists(ABCD) nationwide dapagliflozin audit Baseline Characteristics HbA1c Response to Dapagliflozin Weight & BMI Response to Dapagliflozin HbA1c and Weight Data HbA1c and Weight Data Systolic Blood Pressure Response to Dapagliflozin